 |
|
|
|
|
|
|
|
|
|
|
|
1 to 9 of 9 results |
|
 |
|
|
|
|
|
 |
|
|
|
|
Wyss-Coray T. on NEWS: Plasma Markers for Alzheimer’s—Slowly But Surely?, Our article (Ray et al., 2007) gained a lot of... 4 Sep 2012.
|
|
|
 |
|
|
Wyss-Coray T. on PAPER: Reddy MM. et al., 2011, This report by Kodadek’s group describes a novel approach in the search for disease-specific... 14 Jan 2011.
|
|
|
|
|
|
Wyss-Coray T. on PAPER: O'Bryant SE. et al., 2010, The study presented by the Texas Alzheimer’s Research Consortium (TARC) is one in a series of... 21 Sep 2010.
|
|
|
|
|
|
Wyss-Coray T. on PAPER: Lee JH. et al., 2010, The study by Nixon and colleagues is an absolutely gorgeous paper. It is cell biology at its... 16 Jun 2010.
|
|
|
|
|
|
Britschgi M, Wyss-Coray T. on PAPER: Fillit H. et al., 2009, This interesting retrospective case-control study by Fillit and coauthors finds that treatment... 22 Jul 2009.
|
|
|
|
|
|
Wyss-Coray T. on PAPER: Tobinick EL. et al., 2008, The role of TNFα in the brain is complex. Although there is a lot of indirect evidence that TNFα... 21 Jan 2008.
|
|
|
|
|
|
Wyss-Coray T. on NEWS: Sharp Look at Complement in Genetics of Macular Degeneration, Complement is activated in most forms of neurodegeneration and in AD in particular. Aβ... 1 Sep 2006.
|
|
|
|
|
|
Buckwalter M, Wyss-Coray T. on PAPER: Liu Y. et al., 2006, Interactions between the immune system and the brain are still poorly understood, but it is... 7 May 2006.
|
|
|
|
|
|
Wyss-Coray T. on NEWS: More on TGF-β—Can It Protect against AD?, Q&A with Tony Wyss-Coray. Questions by Tom Fagan.
Q: In your recent paper,... 28 Jan 2004.
|
|
|
|
|
|
|
1 to 9 of 9 results |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
The ALS Forum is a web-based collaborative effort to bring together valuable ALS-related resources for use by researchers worldwide in both academia and industry-based settings.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Should the FDA be allowed to use data from overseas clinical trials? |
|
|
|
|
|
|
|
|
|
|
|
Absolutely, we are running out of viable subjects in the U.S. |
|
|
|
|
|
|
 9 |
|
|
|
|
|
|
|
|
|
|
|
Yes, so long as the data is reliable |
|
|
|
|
|
|
31 |
|
|
|
|
|
|
|
|
|
|
|
No, the trials are not as rigorous |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
No, the data should be repeated in the U.S. |
|
|
|
|
|
|
5 |
|
|
|
|
|
|
|
|
|
|
|
No, the drug sponsors are just trying to cut corners |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
Responses: 51 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
Archived Polls |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
 Antibodies
Cell Lines
Collaborators
Papers
Research Participants
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Home
See our latest Webinar: 
